Seiden B, Weng S, Sun N, et al. - Risk stratification of Black men with low and intermediate-risk prostate cancer using genomic testing led to overall higher NCCN (National Comprehensive Cancer Network) risk classifications. Increased use of genomic testing plays a role in refining risk-stratification within this patient population. Genomic testing in men of African descent may better inform prostate cancer treatment plans.

• A total of 63 Black men deemed eligible for active surveillance by NCCN guidelines, who had OncotypeDx Genomic Prostate Score testing between April 2016 and July 2020, were included.

• Post-Genomic Prostate Score testing, NCCN risk classifications were significantly higher compared with initial classifications (p=0.003, Wilcoxon signed-rank).

• Reclassification to a higher NCCN risk post-genomic testing was seen in 28(28/40, 70%) of patients with discordant risk designations.

• Twenty (64.5%) of favorable intermediate risk patients were reclassified to a higher NCCN risk.

• Finally, 18 patients received definitive treatment.